

Senzime's Interim report January – June 2017

Uppsala, August 31, 2017. **Senzime AB's (publ) Interim report for January – June 2017 is now available on the company's website www.senzime.com.**

Financial information second quarter 2017

- Net sales amounts to KSEK 174 (521)
- Income after financial items amounts to KSEK -2,930 (-2,024).
- Earnings per share before dilution amounts to SEK -0.07 (-0.09).

Financial information January - June 2017

- Net sales amounts to KSEK 174 (543)
- Income after financial items amounts to KSEK -6,901 (-3,876).
- Earnings per share before dilution amounts to SEK -0.18 (-0.20).

For further information, please contact:

Jessica Roxhed, CFO

Tel: +46 703-94 94 98, e-mail: jessica.roxhed@senzime.com

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on August 31st 2017.